Skip to main content
Kent Academic Repository

Donepezil for the treatment of agitation in Alzheimer's disease

Howard, Robert J., Juszczak, Edmund, Ballard, Clive G., Bentham, Peter, Brown, Richard G., Bullock, Roger A., Burns, Alistair, Holmes, Clive, Jacoby, Robin, Johnson, Tony, and others. (2007) Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine, 357 (14). pp. 1382-1392. ISSN 0028-4793. (doi:10.1056/NEJMoa066583) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:2326)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided.
Official URL:
http://dx.doi.org/10.1056/NEJMoa066583

Abstract

Background

Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear.

Methods

We randomly assigned 272 patients with Alzheimer's disease who had clinically significant agitation and no response to a brief psychosocial treatment program to receive 10 mg of donepezil per day (128 patients) or placebo (131 patients) for 12 weeks. The primary outcome was a change in the score on the Cohen-Mansfield Agitation Inventory (CMAI) (on a scale of 29 to 203, with higher scores indicating more agitation) at 12 weeks.

Results

There was no significant difference between the effects of donepezil and those of placebo on the basis of the change in CMAI scores from baseline to 12 weeks (estimated mean difference in change [the value for donepezil minus that for placebo], -0.06; 95% confidence interval [CI], -4.35 to 4.22). Twenty-two of 108 patients (20.4%) in the placebo group and 22 of 113 (19.5%) in the donepezil group had a reduction of 30% or greater in the CMAI score (the value for donepezil minus that for placebo, -0.9 percentage point; 95% CI, -11.4 to 9.6). There were also no significant differences between the placebo and donepezil groups in scores for the Neuropsychiatric Inventory, the Neuropsychiatric Inventory Caregiver Distress Scale, or the Clinician's Global Impression of Change.

Conclusions

In this 12-week trial, donepezil was not more effective than placebo in treating agitation in patients with Alzheimer's disease.

Item Type: Article
DOI/Identification number: 10.1056/NEJMoa066583
Additional information: No DOI/References/Full text/ Official URL or keywords available
Subjects: R Medicine
Divisions: Divisions > Division for the Study of Law, Society and Social Justice > School of Social Policy, Sociology and Social Research
Depositing User: Maureen Cook
Date Deposited: 19 Mar 2008 09:07 UTC
Last Modified: 16 Nov 2021 09:41 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/2326 (The current URI for this page, for reference purposes)

University of Kent Author Information

Bullock, Roger A..

Creator's ORCID:
CReDIT Contributor Roles:

Katona, Cornelius.

Creator's ORCID:
CReDIT Contributor Roles:
  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.